ARTICLE | Company News

Roche exercises option for Ionis HD candidate IONIS-HTTRx

December 15, 2017 3:51 AM UTC

Roche (SIX:ROG: OTCQX:RHHBY) exercised an option to in-license Huntington’s disease (HD) candidate IONIS-HTTRx from Ionis Pharmaceuticals Inc. (NASDAQ:IONS), triggering a $45 million payment to Ionis. The companies partnered in 2013 to develop antisense therapies to treat HD (see BioCentury April 15, 2013)...

BCIQ Company Profiles

Ionis Pharmaceuticals Inc.


BCIQ Target Profiles

Huntingtin (HTT)